Your browser is no longer supported. Please, upgrade your browser.
Catalyst Pharmaceuticals, Inc.
Index- P/E5.36 EPS (ttm)0.67 Insider Own7.00% Shs Outstand103.54M Perf Week1.98%
Market Cap380.41M Forward P/E9.94 EPS next Y0.36 Insider Trans0.25% Shs Float96.41M Perf Month2.56%
Income71.50M PEG- EPS next Q0.09 Inst Own69.90% Short Float10.53% Perf Quarter16.13%
Sales118.20M P/S3.22 EPS this Y190.70% Inst Trans0.93% Short Ratio6.00 Perf Half Y-24.53%
Book/sh1.51 P/B2.38 EPS next Y-47.69% ROA53.30% Target Price- Perf Year-14.29%
Cash/sh1.20 P/C2.99 EPS next 5Y- ROE62.80% 52W Range2.55 - 5.28 Perf YTD7.78%
Dividend- P/FCF- EPS past 5Y26.50% ROI34.60% 52W High-31.82% Beta1.44
Dividend %- Quick Ratio7.60 Sales past 5Y- Gross Margin86.00% 52W Low41.18% ATR0.16
Employees76 Current Ratio7.90 Sales Q/Q-5.20% Oper. Margin34.40% RSI (14)54.25 Volatility4.25% 4.17%
OptionableYes Debt/Eq0.00 EPS Q/Q220.20% Profit Margin60.50% Rel Volume0.98 Prev Close3.67
ShortableYes LT Debt/Eq0.00 EarningsNov 10 AMC Payout0.00% Avg Volume1.69M Price3.60
Recom2.00 SMA203.08% SMA502.64% SMA200-7.66% Volume1,656,277 Change-1.91%
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-07-18Resumed Piper Jaffray Overweight
Oct-05-16Upgrade Piper Jaffray Neutral → Overweight
Apr-26-16Downgrade Piper Jaffray Overweight → Neutral $6 → $1
Sep-30-14Reiterated ROTH Capital Buy $5 → $6
Sep-16-14Reiterated ROTH Capital Buy $3.50 → $5
Sep-15-14Reiterated H.C. Wainwright Buy $5 → $13
Oct-21-13Reiterated Aegis Capital Buy $4 → $5.50
Sep-24-13Initiated Maxim Group Buy $4
Sep-06-13Reiterated Aegis Capital Buy $3.50 → $4
Apr-18-13Initiated Aegis Capital Buy $2.50
Aug-27-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $3.70
Oct-01-09Upgrade Merriman Sell → Neutral
May-29-09Downgrade Merriman Curhan Ford Buy → Sell
May-29-09Downgrade Hapoalim Neutral → Underperform
Dec-15-08Initiated Merriman Curhan Ford Buy
Nov-28-07Initiated Rodman & Renshaw Mkt Outperform $9
Jan-31-07Initiated Stifel Nicolaus Buy $9
Jan-05-07Initiated First Albany Buy $10
Jan-06-21 08:07AM  
Dec-30-20 01:42AM  
Dec-16-20 12:32PM  
Dec-09-20 04:02PM  
Nov-15-20 07:50AM  
Nov-11-20 05:44AM  
Nov-09-20 06:35PM  
Nov-02-20 08:03AM  
Oct-28-20 10:33AM  
Oct-19-20 06:03AM  
Oct-08-20 07:32AM  
Oct-06-20 05:46PM  
Sep-29-20 04:40PM  
Sep-09-20 11:30AM  
Sep-08-20 11:00AM  
Aug-26-20 09:40AM  
Aug-24-20 09:05AM  
Aug-18-20 08:03AM  
Aug-16-20 09:12AM  
Aug-14-20 10:30AM  
Aug-11-20 09:27AM  
Aug-10-20 05:55PM  
Aug-07-20 11:11AM  
Aug-06-20 08:03AM  
Aug-03-20 04:15PM  
Jul-31-20 11:10AM  
Jul-29-20 12:33PM  
Jul-28-20 11:11AM  
Jul-16-20 12:44PM  
Jul-14-20 12:55PM  
Jul-10-20 01:48PM  
Jul-09-20 03:03PM  
Jun-23-20 08:03AM  
Jun-22-20 10:49AM  
Jun-18-20 09:12PM  
Jun-10-20 11:30AM  
Jun-01-20 08:03AM  
May-17-20 08:31AM  
May-14-20 08:18AM  
May-11-20 07:25PM  
May-04-20 08:03AM  
Apr-29-20 10:02AM  
Apr-15-20 11:30AM  
Apr-08-20 06:00AM  
Apr-06-20 09:04AM  
Mar-17-20 06:30AM  
Mar-16-20 05:26PM  
Mar-10-20 08:03AM  
Mar-09-20 12:30PM  
Feb-27-20 08:03AM  
Feb-26-20 08:03AM  
Feb-24-20 09:42AM  
Feb-06-20 08:03AM  
Feb-04-20 08:02AM  
Jan-15-20 08:58AM  
Jan-07-20 09:17AM  
Jan-06-20 08:03AM  
Jan-03-20 05:15PM  
Dec-24-19 06:33AM  
Dec-13-19 02:45PM  
Dec-12-19 11:30AM  
Nov-29-19 09:39AM  
Nov-26-19 08:03AM  
Nov-16-19 08:15AM  
Nov-13-19 02:05PM  
Nov-12-19 06:26PM  
Nov-11-19 05:21PM  
Nov-08-19 10:33AM  
Nov-07-19 06:15PM  
Nov-01-19 12:32PM  
Oct-31-19 10:45AM  
Oct-30-19 06:03AM  
Oct-29-19 03:16PM  
Oct-25-19 08:38AM  
Oct-19-19 09:56PM  
Oct-01-19 03:06PM  
Sep-25-19 08:02AM  
Sep-23-19 02:55PM  
Sep-19-19 10:37AM  
Sep-18-19 09:31AM  
Sep-13-19 10:00AM  
Sep-11-19 04:19PM  
Sep-10-19 03:18PM  
Sep-06-19 09:48PM  
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
INGENITO GARYChief Medical OfficerDec 22Sale3.453,66812,64410,998Dec 28 04:47 PM
O'Keeffe Charles BDirectorSep 30Buy2.997,00020,930560,376Sep 30 02:23 PM
MCENANY PATRICK JPresident and CEOSep 30Buy2.9715,00044,5504,787,693Sep 30 10:55 AM